Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 813 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA... April 15, 2024 A new IARC live webinar on evidence in primary cancer prevention November 11, 2021 How repurposing a drug in a COVID-19 trial could benefit people... March 2, 2021 Want to learn more about Sulforaphanes? December 4, 2020 Load more HOT NEWS First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival... Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas For Children with Retinoblastoma, Disparities Seen across the Globe
